AI Integration And Internal Pipeline Will Accelerate Biologics Growth
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
10 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$16.43
72.1% undervalued intrinsic discount16 Aug
US$4.59
1Y
75.9%7D
8.0%